{"entity":{"id":"nct05326243","kind":"trial","name":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","aka":[],"tldr":"A phase 1/2 trial of CD19-targeted chimeric antigen receptor T-cell in diffuse large B-cell lymphoma and follicular lymphoma, run by Pell Bio-Med Technology Co., Ltd., now recruiting.","summary":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma is a phase 1/2 interventional study registered as NCT05326243 by Pell Bio-Med Technology Co., Ltd., with 49 participants planned, started 2022-05-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: CD19-targeted chimeric antigen receptor T-cell.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05326243","url":"https://clinicaltrials.gov/study/NCT05326243"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05326243","phase":"1/2","setting":"A Phase 1/2 Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of CD19-targeted Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) Therapy in Patients With Relapsed or Refractory B-cell Lymphoma","sponsor":"Pell Bio-Med Technology Co., Ltd.","enrolled":49,"outcomes":[]},"route":"/trials/nct05326243/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}]}}